Identification and drug resistance of rapidly growing Mycobacterium soft tissue infection

doi:10.3969/j.issn.1673-8640.2020.03.003

Abstract

Abstract:

Objective To analyze the drug resistance of rapidly growing Mycobacterium（RGM） and the clinical characteristic of RGM infection patients,and to provide a reference for the further research of RGM. Methods Three isolates of RGM from soft tissue infection patients in Peking University First Hospital for the last 10 years were collected. The 3 RGM isolates were determined by matrix-assisted laser desorption ionization time-of-flight mass spectrometry（MALDI-TOF MS） and sequencing. Drug susceptibility test was performed. The clinical characteristic of RGM infection patients were analyzed. Results The 3 RGM isolates were sensitive to amikacin,tobramycin,imipenem and linezolid,and were resistant to sulfamethoxazole. Levofloxacin,azithromycin and/or rifampicin were used to treat these patients. The patients infected with Mycobacterium fortuitum and Mycobacterium farcinogenes were cured and discharged. The patient with Mycobacterium abscessus was discharged without being completely cured since being in stable condition. Conclusions RGM is resistant to macrolides,which should be avoided in clinical experience.

Key words: Rapidly growing Mycobacterium, Soft tissue infection, Drug susceptibility

CLC Number:

R446.5

ZHOU Jia, JIN Bo, XIAO Nan, HUANG Lei, SUN Liying. Identification and drug resistance of rapidly growing Mycobacterium soft tissue infection[J]. Laboratory Medicine, 2020, 35(3): 200-204.

Figures/Tables 4

References 18

[1]	LIAO T L,LIN C F,CHEN Y M,et al.Risk factors and outcomes of nontuberculous mycobacterial disease among rheumatoid arthritis patients:a case-control study in a TB endemic area[J]. Sci Rep,2016,6:29443.
[2]	Runyon,H.1972. Conservation of the specific epithetfortuitumin the nameof the organism known as Mycobacterium fortuitumda Costa Cruz. Int. [J].Syst. Bacteriol.22:50-51
[3]	BROWN-ELLIOTT B A,PHILLEY J V. Rapidly growing Mycobacteria[J]. Microbiol Spectr,2017,5(1):10.
[4]	KHOOSHABEH R,GRANGE J M,YATES M D,et al.A case report of Mycobacterium chelonae keratitis and a review of mycobacterial infections of the eye and orbit[J]. Tuber Lung Dis,1994,75(5):377-382.
[5]	HAMID M E.Current perspectives on Mycobacterium farcinogenes and Mycobacterium senegalense,the causal agents of bovine farcy[J]. Vet Med Int,2014,2014:247906.
[6]	KUSUNOKI S,EZAKI T.Proposal of Mycobacterium peregrinumsp.nov.,nom. rev.,and elevation of Mycobacterium chelonaesubsp.abscessus(Kubica et al.) to species status:Mycobacterium abscessus comb. nov[J]. Int J Syst Bacteriol,1992.
[7]	WILSON R W,STEINGRUBE V A,BÖTTGER E C,et al. Mycobacterium immunogenum sp. nov.,a novel species related to Mycobacterium abscessus and associated with clinical disease,pseudo-outbreaks,and contaminated metalworking fluids:an international cooperative study on mycobacterial taxonomy[J]. Int J Syst Evol Microbiol,2001,51(Pt 5):1751-1764.
[8]	WALLACE R J Jr,NASH D R,TSUKAMURA M,et al. Human disease due to Mycobacteriums megmatis[J]. J Infect Dis,1988,158(1):52-59.
[9]	Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria,nocardiae,and other aerobic actinomycetes[S]. M24-A2,CLSI,2011.
[10]	SIMONS S,VAN INGEN J,HSUEH P R,et al.Nontuberculous mycobacteria in respiratory tract infections,eastern Asia[J]. Emerg Infect Dis,2011,17(3):343-349.
[11]	GRIFFITH D E,AKSAMIT T,BROWN-ELLIOTT B A,et al. An official ATS/IDSA statement:diagnosis,treatment,and prevention of nontuberculous mycobacterial diseases[J]. Am J Respir Crit Care Med,2007,175(4):744-745.
[12]	FOWLER J,MAHLEN S D.Localized cutaneous infections in immunocompetent individuals due to rapidly growing mycobacteria[J]. Arch Pathol Lab Med,2014,138(8):1106-1109.
[13]	HUANG T S,LEE S S,HSUEH P R,et al.Antimicrobial resistance of rapidly growing mycobacteria in western Taiwan:SMART program 2002[J]. J Formos Med Assoc,2008,107(4):281-287.
[14]	FRANCO-PAREDES C,MARCOS L A,HENAO-MARTÍNEZ A F,et al. Cutaneous mycobacterial infections[J]. Clin Microbiol Rev,2018,32(1):e00069-18.
[15]	YANG S C,HSUEH P R,LAI H C,et al.High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan[J]. Antimicrob Agents Chemother,2003,47(6):1958-1962.
[16]	BROWN B A,WALLACE R J Jr,ONYI G O,et al. Activities of four macrolides,including clarithromycin,against Mycobacterium fortuitum,Mycobacterium chelonae,and Mycobacterium chelonaelike organisms[J]. Antimicrob Agents Chemother,1992,36(1):180-184.
[17]	BROWN-ELLIOTT B A,HANSON K,VASIREDDY S,et al. Absence of a functional erm gene in isolates of Mycobacterium immunogenum and the Mycobacterium mucogenicum group,based on in vitro clarithromycin susceptibility[J]. J Clin Microbiol,2015,53(3):875-878.
[18]	AONO A,MORIMOTO K,CHIKAMATSU K,et al.Antimicrobial susceptibility testing of Mycobacteroides(Mycobacterium) abscessus complex,Mycolicibacterium(Mycobacterium) fortuitum,and Mycobacteroides(Mycobacterium) chelonae[J]. J Infect Chemother,2019,25(2):117-123.

抗菌药物	菌株1		菌株2		菌株3
抗菌药物	鼻疽分枝杆菌/ （μg/mL）	判读结果	偶发分枝杆菌/ （μg/mL）	判读结果	脓肿分枝杆菌/ （μg/mL）	判读结果
阿米卡星	1.5	敏感	1	敏感	2	敏感
亚胺培南	0.38	敏感	0.38	敏感	4	敏感
妥布霉素	2	敏感	0.38	敏感	1.5	敏感
头孢西丁	≥256	耐药	3	敏感	16	敏感
复方磺胺甲噁唑	32	耐药	32	耐药	32	耐药
环丙沙星	0.049	敏感	0.049	敏感	32	耐药
利奈唑胺	0.25	敏感	0.25	敏感	0.5	敏感
克拉霉素	4	中介	4	中介	32	耐药
左氧氟沙星	0.125		0.25		16
利福平	16		4		8
阿奇霉素	≥256		1.5		1.5

抗菌药物	菌株1		菌株2		菌株3
抗菌药物	鼻疽分枝杆菌/ （μg/mL）	判读结果	偶发分枝杆菌/ （μg/mL）	判读结果	脓肿分枝杆菌/ （μg/mL）	判读结果
阿米卡星	1.5	敏感	1	敏感	2	敏感
亚胺培南	0.38	敏感	0.38	敏感	4	敏感
妥布霉素	2	敏感	0.38	敏感	1.5	敏感
头孢西丁	≥256	耐药	3	敏感	16	敏感
复方磺胺甲噁唑	32	耐药	32	耐药	32	耐药
环丙沙星	0.049	敏感	0.049	敏感	32	耐药
利奈唑胺	0.25	敏感	0.25	敏感	0.5	敏感
克拉霉素	4	中介	4	中介	32	耐药
左氧氟沙星	0.125		0.25		16
利福平	16		4		8
阿奇霉素	≥256		1.5		1.5